Immutep Limited
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Marc Voigt
- Full Time Employees
- 41
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Australia Square Sydney NSW Australia 2000
- IPO Date
- Apr 19, 2012
- CIK
- 0001506184
- Website
- immutep.com
- Similar Companies
- Business
- Immutep Limited is a late clinical-stage biotechnology company that develops novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. The company, originally incorporated as Prima BioMed Ltd in 1987 and renamed Immutep Limited in 2017 following the acquisition of Immutep S.A.S., maintains headquarters in Sydney, Australia, and conducts operations globally with clinical trials across multiple continents. Its lead product candidate, eftilagimod alfa (efti or IMP321), a soluble LAG-3Ig fusion protein serving as an antigen-presenting cell agonist, anchors a diversified pipeline including TACTI-004 in phase III for first-line non-small cell lung cancer, TACTI-003 in phase IIb for first-line head and neck squamous cell carcinoma, AIPAC-003 in phase II/III for metastatic HER2-negative breast cancer, EFTISARC-NEO in phase II for soft tissue sarcoma, INSIGHT-003 in phase I/II for non-squamous NSCLC, and INSIGHT-005 in phase I/II for metastatic urothelial cancer, all typically combined with checkpoint inhibitors such as KEYTRUDA (pembrolizumab) or BAVENCIO (avelumab); additional candidates encompass IMP761, an agonist LAG-3 antibody in phase I for autoimmune diseases including ulcerative colitis and psoriasis, IMP731, a depleting LAG-3 antibody for autoimmune indications, and out-licensed programs with Novartis such as LAG525 in phase II for solid tumors, blood cancers, and triple-negative breast cancer. Immutep maintains strategic collaborations with Merck & Co., Novartis, GlaxoSmithKline, EOC Pharma, and Laboratory Corporation of America Holdings, supporting clinical supply and development; recent advancements include meeting the primary endpoint in the EFTISARC-NEO phase II trial for neoadjuvant efti in soft tissue sarcoma with data presented at ESMO Congress 2025, positive FDA feedback on late-stage development of efti in head and neck cancer for CPS <1 patients, full recruitment and ongoing data analysis in AIPAC-003, translational data and pathologic response highlights from EFTISARC-NEO at CTOS 2025, an update advancing TACTI-004 phase III enrollment, and a new research collaboration with George Washington University Cancer Center for neoadjuvant efti evaluation.
Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm
IMMP DEADLINE: Levi & Korsinsky Reminds Immutep Limited Investors of Upcoming Securities Class Action Deadline
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP
IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
IMMP INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026
IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
ROSEN, A LONGSTANDING FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMP
Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm